Format

Send to

Choose Destination
Hematology Am Soc Hematol Educ Program. 2009:507-19. doi: 10.1182/asheducation-2009.1.507.

Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.

Author information

1
Department of Lymphoma/Myeloma, M D Anderson Cancer Center, Houston, TX 77030, USA. ayounes@mdanderson.org

Abstract

Although classical Hodgkin lymphoma (HL) is considered one of the most curable human cancers, the treatment of patients with relapsed and refractory disease, especially those who relapse after autologous stem cell transplantation, remains challenging. Furthermore, because the median age of the patients is in the mid-30s, the impact of early mortality on the number of years lost from productive life is remarkable. Patients with HL whose disease relapses after stem cell transplantation are rarely cured with current treatment modalities. New drugs and novel treatment strategies that are based on our understanding of the disease biology and signaling pathways are needed to improve treatment outcome for these patients. This review will focus on emerging new treatment modalities that are currently under investigation for patients with relapsed classical HL.

PMID:
20008236
DOI:
10.1182/asheducation-2009.1.507
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center